The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Korea GSK announced on the 29th that it will begin administering the world's first respiratory syncytial virus (RSV) vaccine, Arexvy. It will be available for vaccination at hospitals and clinics ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

In GSK’s suit against Pfizer, the British pharma was seeking monetary damages or royalties and potentially a permanent injunction on the commercialization of Pfizer’s RSV vaccine in the U.S.

GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons ...

GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus ...